First, our study population consisted of patients with T2D on hypoglycemic treatment compared with patients without diabetes in the pilot study
Sadaghian Sadabad M, von Martels JZ, Khan MT, Blokzijl T, Paglia G, Dijkstra G, et al
Another class of medications initially developed for the treatment of high blood glucose in patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i), has also been demonstrated to reduce cardiovascular risk, with corresponding FDA product label changes and professional society recommendations endorsing their use
physician notes documenting the prescribing decision
No information regarding chromatin accessibility and HPTMs was found on CI mitigation for pome and stone fruits